Modafinil in nootropic tier lists: why rankings disagree

Key points

• Three popular X posts treat modafinil in three ways: tier D on a cognition list, a “loves” entry on a dopamine graphic, and absent from two other lists [8][9][10]. None cites a study or states its criteria.
• The disagreement is not a contradiction. The lists appear to measure different things, and none says what.
• Published trials pool to small effects in rested healthy adults (g = 0.10 and SMD 0.12), with clearer but short-lived effects under sleep deprivation [3][4][6].
• A personal ranking mixes subjective effect, goal, risk tolerance and who happened to try the drug. Randomized trials were built to separate those.
• Each list could be tested if it disclosed a few things; the last section names them.

What do the three lists say?

The posts are the posters’ claims. We read them through the fxtwitter mirror and took tier placements from the images [8][9][10].

Post	Date	Where modafinil appears
@dex7official, “THE ONLY TRUE COGNITIVE ENHANCEMENT TIER LIST (NO COPES EDITION)” [8]	20 Oct 2026	Tier D, with armodafinil, Semax, Selank, L-theanine and alpha-GPC; coffee is a tier higher, in C
@theriac33, “What your dopamine: Loves / Hates” [9]	2 Nov 2026	In the “loves” column, next to exercise, L-tyrosine and bromantane
@Hoostethics, looksmaxxing list (22 Oct) and “most cope supplements” list (15 Oct) [10]	2026	Not present on either

The @dex7official list puts methamphetamine, Vyvanse and Adderall XR in S and ketamine alongside them, and places creatine and BPC-157 in F. A reader who treats that list as a measurement would conclude modafinil is a weak option. A reader of the @theriac33 graphic would conclude it is good for dopamine. Both readings come from the same drug [8][9]. For the rest of the first list, see our cognitive enhancement tier list check; for the dopamine graphic, dopamine optimization claims check.

Why individual rankings diverge

They measure different outcomes

“Cognitive enhancement” can mean staying awake, sustained attention, working memory, planning, mood, motivation or output at work. Published trials of modafinil show how much the answer depends on the test. A systematic review of healthy, non-sleep-deprived adults found that on simple tests only “half” of studies showed gains in attention and learning and memory, a few reported impaired divergent creative thinking, and complex tasks showed more consistent gains in attention, executive function and learning [5]. A ranking that does not say which of these it means cannot be compared with one that does.

The @theriac33 graphic is a different kind of claim again. “Loves” is not a cognitive outcome. The one human imaging study we opened, a 2009 JAMA pilot in 10 healthy men, reported that modafinil lowered binding of a dopamine-receptor tracer in the caudate, putamen and nucleus accumbens, which the authors read as raised extracellular dopamine, and reduced binding of a transporter tracer, which they read as transporter blockade [7]. That is a measured brain effect in a very small sample. It does not show that a person feels or performs better. The FDA label says the mechanism by which modafinil promotes wakefulness “is unknown” [1].

They reflect the poster’s goal and risk tolerance

The @dex7official list ranks Desoxyn, Vyvanse and Adderall XR in its top tier [8]. A ranker who values strong, immediate stimulation will put a milder drug lower. A ranker who values the lowest risk may weight it higher. Neither list says which it used, and a tier is a single dimension that hides this trade-off.

Risk is part of the picture the lists leave out. The label reports headache in 34% of modafinil patients versus 23% on placebo and a rare risk of serious skin reactions [1]. A ranking built on effect alone and one that discounts for harm will place the same drug differently.

Selection and survivorship shape what a poster has seen

We have no information about how any of these posters built their lists. What can be said is general: people who try a drug and stop because it did nothing, or because it caused side effects, are less likely to be among its vocal fans. People who keep using it are more likely to rank it. A list from one person reflects the people and doses they know and does not sample from all users. Trials differ in this respect because participants are assigned to drug or placebo regardless of what they expect.

Expectation matters too. The authors of the 2020 meta-analysis wrote that the evidence does not support the common belief that these drugs are effective cognitive enhancers in healthy adults [4]. We could not confirm the Roberts abstract’s wording beyond the summary returned by Europe PMC, so we paraphrase rather than quote.

Anecdote cannot separate drug, placebo and context

Someone who takes modafinil on a good day, after sleeping well, with a deadline, may credit the drug. Without a placebo arm and blinding, nothing separates drug from expectation, caffeine intake, sleep or motivation. A randomized trial removes that by chance allocation. In the 85-hour sleep-deprivation trial, for example, 12 participants per group got placebo, caffeine, dextroamphetamine or modafinil, and all three active drugs beat placebo on vigilance for roughly 2 to 4 hours [6]. A personal impression cannot say whether coffee would have done the same, which is the exact comparison the @dex7official list implies. Our modafinil vs caffeine article covers those head-to-head trials.

The lists state no criteria

No post defines what a tier means, what was compared, over what period, at what intensity or for whom. “Cope” in the @Hoostethics supplement list is also undefined in the post [10]. A ranking with no criteria cannot be wrong, and it cannot be right either. It can only be popular: the @dex7official post had 6,522 likes and 1.2M views when we fetched it, the @theriac33 post 310 likes and 29k views [8][9]. Engagement does not measure accuracy.

What the published evidence says about modafinil

Rested, healthy adults. A 2019 meta-analysis pooled 19 placebo-controlled single-dose trials (67 effect sizes) and found a small, significant overall benefit, g = 0.10 (95% CI 0.05 to 0.15). Dose and psychiatric status did not moderate it, and the authors concluded the evidence shows “only limited potential” for modafinil as a cognitive enhancer [3]. A 2020 meta-analysis of 47 studies across three drugs found an overall modafinil effect of SMD 0.12 (p = .01), compared with 0.21 for methylphenidate and none for d-amphetamine [4]. Both are mostly short laboratory experiments, so they say little about months of real-world use [3][4].

Sleep deprivation. Effects are clearer. The 2005 trial above enrolled 48 healthy young adults; modafinil, caffeine and dextroamphetamine each improved psychomotor vigilance and alertness, executive-function results were mixed, and the authors tied the duration to each drug’s elimination rate [6]. This is a different situation from a rested person at a desk.

Not studied well. Long-term use in healthy people, repeated use outside sleep deprivation, and performance on real tasks. Our modafinil guide covers those gaps and the study details.

Verdicts on the lists. @dex7official’s D placement for modafinil: partly supported, since small pooled effects fit a low rank [3][4], though no criteria are given, so the rank cannot be tested. @theriac33’s “loves”: partly supported, because a PET pilot of 10 men found raised extracellular dopamine [7], but “loves” is not a measured outcome and the wakefulness mechanism is listed as unknown [1]. @Hoostethics: no claim made.

Regulatory status

Checked 8 November 2026 against sources we opened. United States: the FDA label covers excessive sleepiness in adults with narcolepsy, obstructive sleep apnea or shift work disorder; modafinil is a Schedule IV controlled substance and prescription-only (label revised 2/2025) [1]. European Union: after an EMA review (CHMP opinion 18 November 2010; Commission decision 27 January 2011) it is indicated only for narcolepsy [2]. UK and Germany: not rechecked for this article; see the modafinil guide. Use for cognition in healthy people is off-label. It is a licensed medicine, so “research use only” labelling does not apply.

Risks and unknowns

The label lists headache, nausea, nervousness, anxiety and insomnia as more common than on placebo in patients with sleep disorders, serious rash including Stevens-Johnson syndrome, psychiatric reactions, and an effect on hormonal contraceptives [1]. Pregnancy data are conflicting. These figures come from patients, not healthy volunteers, and the long-term effects of non-prescribed use are not well studied. We did not reopen the full risk literature for this article; see the guide.

What each list would need to disclose to be testable

This is a fair standard, and it applies to most tier lists, not only these three.

• @dex7official: the outcome behind each tier (alertness, memory, output, mood), the user group, whether the tiers consider risk, and whether “coffee” and “modafinil” were compared at the same intensity. Without these, a one-tier gap cannot be checked against trials such as [6].
• @theriac33: what “loves” means (a measured dopamine change, a feeling, a behaviour), how it was assessed, and for whom. The graphic also labels a flavone structure “Prolactin”, which our transcription flagged as an error [9].
• @Hoostethics: whether absence is a judgement or just scope. Modafinil’s absence from a looksmaxxing list and a supplement list may only mean it was out of scope; the posts do not say [10].

For any of the three, the strongest improvement would be a stated method: what was ranked, on what evidence, and by whom.

Frequently asked questions

Why is modafinil in tier D on one list and “loves” on another?

The lists do not say what they measure. One appears to be about cognitive enhancement overall and the other about dopamine, and neither states criteria, so their placements are not in conflict [8][9].

Do trials support ranking modafinil below coffee?

Not directly. No pooled analysis ranks them. In small sleep-deprivation trials, caffeine and modafinil both beat placebo for roughly the first 2 to 4 hours [6]. The caffeine article linked above covers sizes and limits.

Does a dopamine effect mean a cognitive benefit?

No. A 10-man PET pilot found raised extracellular dopamine and transporter occupancy [7], but meta-analyses of cognitive tests in healthy adults found small effects [3][4].

Can anecdotes be trusted at all?

They can raise questions, such as unexpected side effects. They cannot separate drug from placebo, or show how common an experience is.

Sources

1. Apotex Corp., “PROVIGIL (modafinil) tablets, prescribing information”, DailyMed (revised 2/2025; listing updated 27 Aug 2025). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0391f182-1958-9fef-a944-53b229ce99e7
2. EMA, “Modafinil - referral” (CHMP opinion 18 Nov 2010; Commission decision 27 Jan 2011). https://www.ema.europa.eu/en/medicines/human/referrals/modafinil
3. Kredlow MA et al., “The efficacy of modafinil as a cognitive enhancer: a systematic review and meta-analysis”, J Clin Psychopharmacol 2019;39:455-61 (abstract, read via Europe PMC because PubMed blocked us). https://pubmed.ncbi.nlm.nih.gov/31433334/
4. Roberts CA et al., “How effective are pharmaceuticals for cognitive enhancement in healthy adults?”, Eur Neuropsychopharmacol 2020;38:40-62 (abstract via Europe PMC; funding not shown). https://pubmed.ncbi.nlm.nih.gov/32709551/
5. Battleday RM, Brem AK, “Modafinil for cognitive neuroenhancement in healthy non-sleep-deprived subjects: a systematic review”, Eur Neuropsychopharmacol 2015;25:1865-81 (abstract via Europe PMC). https://pubmed.ncbi.nlm.nih.gov/26381811/
6. Wesensten NJ, Killgore WD, Balkin TJ, “Performance and alertness effects of caffeine, dextroamphetamine, and modafinil during sleep deprivation”, J Sleep Res 2005;14:255-66 (abstract via Europe PMC). https://pubmed.ncbi.nlm.nih.gov/16120100/
7. Volkow ND et al., “Effects of modafinil on dopamine and dopamine transporters in the male human brain”, JAMA 2009;301:1148-54 (abstract via Europe PMC). https://pubmed.ncbi.nlm.nih.gov/19293415/
8. @dex7official, “THE ONLY TRUE COGNITIVE ENHANCEMENT TIER LIST (NO COPES EDITION)” (20 Oct 2026). https://x.com/dex7official/status/2112691493261484516 (text read through the fxtwitter mirror; placements read from the image on 2026-11-08; a claim, not evidence)
9. @theriac33, “What your dopamine loves / hates” (2 Nov 2026). https://x.com/theriac33/status/2117361887457505469 (fxtwitter mirror; image read 2026-11-08; a claim, not evidence)
10. @Hoostethics, “ranking looksmaxxing techniques” (22 Oct 2026) https://x.com/Hoostethics/status/2113302148750758106 ; “ranking the most cope supplements” (15 Oct 2026) https://x.com/Hoostethics/status/2110728908735979632 (fxtwitter mirror; images read 2026-11-08; claims, not evidence)

This article is information, not medical advice.